Literature DB >> 2005641

Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards.

R Geleziunas1, A McQuillan, A Malapetsa, M Hutchinson, D Kopriva, M A Wainberg, J Hiscott, J Bramson, L Panasci.   

Abstract

Resistance to the nitrogen mustards in patients with chronic lymphocytic leukemia (CLL) correlates with an enhanced removal of melphalan-induced DNA interstrand cross-links. This finding suggests that DNA repair enzymes may be involved in this process. The activity of 3-methyladenine-DNA glycosylase, which can release altered bases, including adducts at the N-7 position of guanine, was increased significantly in lymphocytes from patients with resistant CLL compared with those from untreated CLL patients. Since glycosylase activity varies with cell proliferation, the amount of [3H]thymidine incorporated into DNA was determined and found to be elevated almost threefold in lymphocytes from patients with resistant CLL. The ratio of glycosylase activity to level of thymidine incorporation did not differ between these two groups of patients. Northern blot analysis of ERCC1 gene (a putative DNA repair enzyme involved in nucleotide excision repair) expression in lymphocytes from patients with CLL revealed multiple gene transcripts (1.1, 3.4, and 3.8 kilobases). In addition, analysis of two samples revealed the presence of a 2.6-kilobase transcript. The 2.6-kilobase transcript was recognized by specific RNA probes that hybridize to antisense ERCC1 transcripts. Levels of expression of the 1.1-kilobase protein encoding transcript in lymphocytes from patients with resistant CLL were increased twofold to threefold above those of untreated patients with CLL. These results indicate that increased expression of ERCC1 and increased activity of 3-methyladenine-DNA glycosylase occur with the development of resistance to the nitrogen mustards in patients with CLL, suggesting a role for enhanced DNA repair in this process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2005641     DOI: 10.1093/jnci/83.8.557

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  16 in total

1.  Alkylator-induced DNA excision repair in human leukemia CCRF-CEM cells in vitro, measured using the single-cell gel electrophoresis (comet) assay.

Authors:  Takahiro Yamauchi; Yasukazu Kawai; Takanori Ueda
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Involvement of the Ras/extracellular signal-regulated kinase signalling pathway in the regulation of ERCC-1 mRNA levels by insulin.

Authors:  W Lee-Kwon; D Park; M Bernier
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

Review 3.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Leukemia cells are sensitized to temozolomide, carmustine and melphalan by the inhibition of O6-methylguanine-DNA methyltransferase.

Authors:  Hajime Arai; Takahiro Yamauchi; Kanako Uzui; Takanori Ueda
Journal:  Oncol Lett       Date:  2015-06-02       Impact factor: 2.967

5.  Strategic down-regulation of DNA polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA damaging agents.

Authors:  J K Horton; D K Srivastava; B Z Zmudzka; S H Wilson
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

6.  Mutational analysis of the human nucleotide excision repair gene ERCC1.

Authors:  A M Sijbers; P J van der Spek; H Odijk; J van den Berg; M van Duin; A Westerveld; N G Jaspers; D Bootsma; J H Hoeijmakers
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

7.  Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.

Authors:  Amal A El-Mabhouh; Mary L Ayres; Elizabeth J Shpall; Veerabhadran Baladandayuthapani; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2014-04-18       Impact factor: 22.113

8.  Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

Authors:  M Dabholkar; J Vionnet; F Bostick-Bruton; J J Yu; E Reed
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 9.  Kinetic resistance to anticancer agents.

Authors:  M T Dimanche-Boitrel; C Garrido; B Chauffert
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

Authors:  Judith E Karp; Rebecca M Ricklis; Kumudha Balakrishnan; Janet Briel; Jacqueline Greer; Steven D Gore; B Douglas Smith; Michael A McDevitt; Hetty Carraway; Mark J Levis; Varsha Gandhi
Journal:  Blood       Date:  2007-06-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.